Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in Metastatic Pancreatic Cancer
NCT03553004Phase 2Unknown
- Sponsor
- University of Kansas Medical Center
- Start
- Jan 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in pancreatic cancer (PC), sponsored by University of Kansas Medical Center. Primary endpoint: Objective Response Rate at 8 weeks. Status: unknown.
02
Drugs
niraparib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03553004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553004.